Ultrasound zaps brain pathways in quest to understand psychiatric disorders
NCT ID NCT07099950
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses low-intensity focused ultrasound to temporarily change activity in deep brain areas involved in mood and anxiety. Researchers will scan the brains of 66 healthy adults before and after ultrasound to see how it alters communication between key regions. The goal is to learn how this technique might one day be used to treat conditions like depression or anxiety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- low-intensity focused ultrasound
- What this could lead to
- If successful, this could help researchers understand how to use ultrasound to adjust brain circuits, potentially leading to new treatments for psychiatric disorders.
- What could go wrong
- This is an early-stage study in healthy volunteers, not patients. It only measures brain activity changes, not clinical benefits, and may not translate into effective therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY CONTROLS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Laureate Institute for Brain Research
RECRUITINGTulsa, Oklahoma, 74136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mining mountains of data to outsmart diabetes complications
- Psilocybin without the trip: scientists hunt for a microdose that skips hallucinations
- Manitoba DNA hunt could revolutionize schizophrenia care
- Brain insulin study aims to uncover why antipsychotics cause weight gain
- Ketone drink may boost brain fuel in prediabetes
- Experimental drug VVZ-2471 gets first safety check in humans